Atopic Dermatitis

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

Dr Golant continues with the case of the 38-year old patient with atopic dermatitis and explore effective strategies for navigating treatment selection and planning in this condition, focusing on discussing options with patients and instilling confidence in the chosen approach.

Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.

Dr Linda Stein-Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.

Treatment also shifted the expression of key biomarkers in atopic dermatitis toward non-lesional levels, according to a recent study.

Ruth Ann Vleugels, MD, MPH, MBA, delves into patient-specific considerations and action plans when on a JAK inhibitor, including shingles prevention and management.

Experts in dermatology review the rapid itch relief provided by topical ruxolitinib cream and attribute its fast-acting efficacy to its mechanism of action targeting a variety of interleukins.

Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.

Ruth Ann Vleugels, MD, MPH, MBA, shares insights that she gives her own residents on JAK inhibitor selection, risks, benefits, and data available.

In one study, researchers were unable to detect any changes in the gut microbiome of patients treated with tapering dose of steroids or a probiotic mixture.

David Rosmarin, MD, acknowledges opportunities for further research in diverse populations to continue updating AD treatment guidelines.

David Rosmarin, MD, addresses the research gaps in recommendations for systemic therapies in atopic dermatitis in the latest guidelines.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

Mark Lebwohl, MD, discusses the rapid expansion of therapeutic options, including targeted drugs like JAK inhibitors and IL-13 treatments for atopic dermatitis, paralleling the progress seen in psoriasis treatment over the last decade.

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Alexandra Golant, MD, shares how sleep improvement is measured and the difference an effective treatment makes for the patient’s entire family.

Alexandra Golant, MD, explains why she is confident in the latest safety and efficacy data from ruxolitinib trials to treat pediatric patients with atopic dermatitis.

Researchers address the persisting gaps in managing mental health comorbidities within the framework of existing clinical practice guidelines.

Alexandra Golant, MD, presents the case of a 38-year-old Caucasian male construction worker, diagnosed with moderate AD at age 15, and his treatment history with various interventions and physician referral considerations.

Dr. Golant discusses the role of disease severity in her selection of atopic dermatitis treatments, particularly noting the characterization of hand and foot involved patients as often moderate cases, and highlighting the rapid response observed in these areas when treated.

The risk of upper respiratory infection-related mortality was notably diminished in the study's dupilumab cohort.

Paller shares early findings from the award winning poster on PEDISTAD trial and its clinical implication for children with atopic dermatitis.

Brad Glick, DO, MPH, says it is essential to consider patient lifestyles when choosing atopic dermatitis therapies.

Brad Glick, DO, MPH, emphasizes the importance of personalized and inclusive communication in choosing therapeutics for atopic dermatitis.

Brian Kim, MD, underscores the critical gap in addressing severe itch in atopic dermatitis, often overshadowed by the visible manifestations of skin rash.

Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.

Christopher Bunick, MD, PhD, expands on how clinicians can personalize treatment plans for each patient.